Gosset Ownership
Private
Employees
~7
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
AndroScience General Information
The company has multiple preclinical programs targeting the androgen receptor (AR) and STAT3/STAT5A for various indications including prostate cancer and liver cancer.
Contact Information
Primary Industry
Biotech
Corporate Office
San Diego, California
United States
United States
Drug Pipeline
ARD Enhancer
Phase 2Key Partnerships
James Graham Brown
AndroScience Funding
No funding data available
To view AndroScience's complete valuation and funding history, request access »